跳至主要内容
临床试验/NCT02064296
NCT02064296已完成不适用

Neuroimaging Approaches to Deconstructing Acupuncture for Chronic Pain

University of Michigan1 个研究点 分布在 1 个国家目标入组 121 人开始时间: 2014年12月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
121
试验地点
1
主要终点
Change in Brain Connectivity With Acupuncture Treatment

研究概览

简要总结

The aim of this study is to evaluate the impact of electro-acupuncture in pain processing on patients with fibromyalgia (FM). The investigators hypothesize that electro-acupuncture is effective for FM because it functions as a desensitization therapy, which when applied repeatedly over multiple treatment sessions, gradually habituates the nervous system to continuing pain and sensory signaling.

详细描述

This study design has two components: 1) a cross sectional assessment of brain chemistry, connectivity and response to pain in healthy controls and age- and sex-matched fibromyalgia patients, and 2) a longitudinal assessment of the same outcomes in fibromyalgia patients randomized to either electro-acupuncture (EA) or laser acupuncture.

The investigators will evaluate 80 fibromyalgia patients who will receive acupuncture treatment twice a week for 4 weeks, for a total of 8 treatments. Baseline data from these patients will be compared to results from 40 pain-free controls.

Participants will undergo experimental pain assessments as well as brain neuroimaging.

Note added after completion of study data gathering: Within the registration in ClinicalTrials.gov and the informed consent, one arm was referred to as "non-traditional acupuncture". In fact, this was a control arm, receiving mock laser acupuncture (Vita Laser 650, Lhasa OMS). They received 2 treatments per week for 4 weeks. As consented, they were told, with IRB permission, that they were receiving non-traditional laser acupuncture. This deception was essential to maintaining scientific integrity of the masking.

The laser acupuncture device (Vita Laser 650, Lhasa OMS) was positioned over all of the same acupoints used in electro-acupuncture (EA), but was turned off during treatment sessions. There was no palpation prior to positioning these devices, and there was no physical contact between device and skin.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
Female
接受健康志愿者
是

入选标准

  • •for Fibromyalgia Participants
  • •Have self-reported FM symptoms for at least one year and also meet the Wolfe et al 2011 criteria for Fibromyalgia.
  • •Continued presence of pain more than 50% of days.
  • •Pain greater than a certain threshold on the Visual Analog Scale (VAS) for pain; 7-day recall; [Note: The VAS is widely used in clinical pain research and as such we chose to use it for inclusion criteria and for clinical pain assessment below. Within our group numerical ratings scales 0-100 are more commonly used in quantitative sensory assessment, and as such we chose to use NRS scales for evoked pain assessments below.]
  • •Willing to limit the introduction of any new medications or treatment modalities for control of FM symptoms during the study.
  • •Able to travel to the study site to receive acupuncture treatments up to two times weekly.
  • •Over 18 and under 65 years of age.
  • •Right-handed.
  • •Capable of giving written informed consent.
  • •Inclusion Criteria for Healthy Control Participants
  • •Over 18 and under 65 years of age.
  • •Right-handed.
  • •Do not have fibromyalgia or an associated pain disorder, including: migraine, temporomandibular joint disorder (TMJ), chronic pelvic pain (CPP), or chronic fatigue syndrome (CFS).
  • •Pain less than a certain threshold on the Visual Analog Scale (VAS) for pain; 7-day recall
  • •Willing to complete all study procedures.
  • •Capable of giving written informed consent.

排除标准

  • •for Fibromyalgia Participants:
  • •Acupuncture within last 6-months.
  • •Presence of a known coagulation abnormality, thrombocytopenia, or bleeding diathesis that may preclude the safe use of acupuncture.
  • •Presence of a concurrent autoimmune or inflammatory disease such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, etc., or any other chronic pain condition with pain greater than fibromyalgia pain.
  • •Peripheral neuropathy of know cause that interferes with activities of daily living.
  • •History of vascular surgery in lower limbs or current lower limb vascular dysfunction.
  • •History of head injury with substantial loss of consciousness.
  • •Routine daily use of narcotic analgesics, marijuana or have a history of substance abuse in the past 24 months as determine by subject self-report.
  • •Stimulant medications, such as those used to treat ADD/ADHD (e.g., amphetamine/ dextroamphetamine [Adderall®], methylphenidate, dextroamphetamine), or the fatigue associated with sleep apnea or shift work (e.g., modafinil), are excluded.
  • •Concurrent participation in other therapeutic trials.
  • •Pregnant or nursing.
  • •Severe psychiatric illnesses (current schizophrenia, major depression with suicidal ideation, substance abuse within two years).
  • •Contraindications to fcMRI, fMRI, or 1H-MRS methods. These may include but are not limited to: surgical clips, surgical staples, metal implants, and certain metallic dental material. [Note: a more formal description of contraindications for MRI is present in our DSM Plan].
  • •Use of over the counter pain medications (NSAIDs, etc.) on the day of MRI scan.
  • •Use of as needed narcotic pain medication 48 hours prior to MRI scan.
  • •Current, habitual, or previous use within the last 12 months of artificial nails, nail enhancements, or nail extensions that cover any portion of either thumbnail. Exceptions, including brief and/or occasional use, may be permissible at the discretion of the principle investigator.
  • •Any impairment, activity or situation that in the judgment of the Study Coordinator or Principal Investigator that would prevent satisfactory completion of the study protocol.
  • •Contraindications to the Electrostimulator device: Participants with electrical implants (i.e. pacemakers, defibrillators), cardiac rhythmic disorders, seizure disorders, any skin disorder in the vicinity of the electrode or an malignant diseases in the region of application. (Fibromyalgia participants only)
  • •Exclusion Criteria for Healthy Control Participants:
  • •Have a diagnosis of fibromyalgia or meet the Wolfe et al 2011 criteria for Fibromyalgia.
  • •Presence of a concurrent autoimmune or inflammatory disease such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, etc. that causes pain.
  • •Routine daily use of narcotic analgesics, marijuana or have a history of substance abuse in the past 24 months as determine by subject self-report.
  • •Stimulant medications, such as those used to treat ADD/ADHD (e.g., amphetamine/ dextroamphetamine [Adderall®], methylphenidate, dextroamphetamine), or the fatigue associated with sleep apnea or shift work (e.g., modafinil), are excluded.
  • •Concurrent participation in other therapeutic trials.
  • •Pregnant or nursing.
  • •Peripheral neuropathy of know cause that interferes with activities of daily living.
  • •History of vascular surgery in lower limbs or current lower limb vascular dysfunction.
  • •History of head injury with substantial loss of consciousness.
  • •Severe psychiatric illnesses (current schizophrenia, major depression with suicidal ideation, substance abuse within two years).
  • •Contraindications to fcMRI, fMRI, or 1H-MRS methods. (see above section)
  • •Use of over the counter pain medications (NSAIDs, etc.) on the day of MRI scan.
  • •Use of as needed narcotic pain medication 48 hours prior to MRI scan.
  • •Current, habitual, or previous use within the last 12 months of artificial nails, nail enhancements, or nail extensions that cover any portion of either thumbnail. Exceptions, including brief and/or occasional use, may be permissible at the discretion of the principle investigator.
  • •Any impairment, activity or situation that in the judgment of the Study Coordinator or Principal Investigator that would prevent satisfactory completion of the study protocol.

研究组 & 干预措施

Controls

No Intervention

Healthy pain free controls will be recruited for comparison with fibromyalgia patients.

Non-Traditional Acupuncture

Active Comparator

40 fibromyalgia patients will be randomized to non-traditional laser acupuncture (Vita Laser 650, Lhasa OMS). They will receive 2 treatments per week for 4 weeks.

干预措施: Laser acupuncture (Non-traditional Acupuncture) (Device)

Traditional Acupuncture

Active Comparator

40 fibromyalgia patients will be randomized to receive electro acupuncture (AS Super 4 digital needle stimulator, Harmony Medical Co) . They will receive 2 treatments per week for 4 weeks.

干预措施: Needle acupuncture (Traditional Acupuncture) (Device)

结局指标

主要结局

Change in Brain Connectivity With Acupuncture Treatment

时间窗: Baseline and 4 weeks

Brain connectivity will be assessed at baseline and following either electro-acupuncture or mock laser acupuncture. Primary somatosensory cortex to insula connectivity. (Z-stat) A positive Z score reflects positive correlation in FMRI signal between different between brain areas. A negative Z score represents anti-correlation between in FMRI signal between brain regions. These scores reflect either positive connectivity or inhibitory connectivity. A mean of 0 represents no correlation or connectivity between regions.

Brain Neurocircuitry Underlying Chronic Pain (Percent of Time of a Somato-sensory Cortex Coactivation Pattern)

时间窗: At baseline

Characterize the altered somatosensory-related neurocircuitry underlying chronic pain in FM, as shown by the difference in brain connectivity between healthy controls and FM patients as measured by FMRI (occurrence rate of co-activation pattern). For each arm, the coactivation pattern was assessed at rest and during a pressure pain stimulation. This is measured by the percent of scan time that an individual's brain displayed a particular coactivation pattern related to the somatosensory system.

次要结局

  • Change in Brain Neurochemistry of Gama-aminobutyric Acid (GABA) Within the Anterior Insular Cortex With Acupuncture Treatment(Baseline and 4 weeks)
  • Change in Brain Neurochemistry of Combined Glutamate and Glutamine (Glx) Within the Anterior Insular Cortex With Acupuncture Treatment(Baseline and 4 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Richard Harris

Assistant Professor

University of Michigan

研究点 (1)

Loading locations...

相似试验